Allakos Inc. (ALLK)
| Previous close | 5.77 |
| Open | 5.61 |
| Bid | 5.56 x 800 |
| Ask | 5.57 x 1100 |
| Day's range | 5.45 - 5.73 |
| 52-week range | 2.54 - 112.87 |
| Volume | |
| Avg. volume | 2,056,088 |
| Market cap | 304.155M |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.10 |
| Earnings date | 07 Nov 2022 - 11 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.75 |
- Simply Wall St.
After losing 95% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gain
A look at the shareholders of Allakos Inc. ( NASDAQ:ALLK ) can tell us which group is most powerful. And the group that...
- GlobeNewswire
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
SAN CARLOS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten offering of 29,882,000 shares of its common stock at an offering price of $5.02 per share. Investors who have agreed to purchase shares in the offering include Logos Capital, Alta Partners, Braidwell LP, BVF Partners L.P., Commodore Capital, Deep
- GlobeNewswire
Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)
Top-line Phase 2b results expected in the second half of 2023 Figure 1 - Change from baseline in UAS7 in omalizumab naïve cohort (n=13) Source: Allakos Inc. Figure 2 - UCT and UAS7 response in Omalizumab Naïve Cohort (n=13) Source: Allakos Inc. Figure 3 - Change from baseline in UAS7 in omalizumab refractory cohort (n=7) Source: Allakos Inc. SAN CARLOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for th
